易聯眾(300096.SZ):醫控公司擬將易方科技52%股權轉讓給深圳盛投和
格隆匯 4 月 2日丨易聯眾(300096.SZ)公佈,公司全資子公司易聯眾健康醫療控股有限公司(“醫控公司”)持有廈門易聯眾易方科技有限公司(“易方科技”)52%股權,公司控股子公司易聯眾民生(廈門)科技有限公司(“民生科技”)持有易方科技20%股權。
為優化公司資產結構及資源配置,醫控公司擬將持有的易方科技52%股權以人民幣1249萬元的價格轉讓給深圳盛投和科技諮詢有限公司(“深圳盛投和”或“受讓方”)。
此次股權轉讓後,醫控公司不再持有易方科技股權,民生科技仍持有易方科技20%股權,公司不再將易方科技納入合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.